SML2897
Flomoxef Sodium
≥97% (HPLC)
Synonym(s):
(6R,7R)-7-[[2-[(Difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt, 6315-S Sodium salt, FMOX Sodium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C15H17F2N6O7S2 · Na
CAS Number:
Molecular Weight:
518.45
NACRES:
NA.77
UNSPSC Code:
12352200
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Flomoxef is a semisynthetic oxacephem antibiotic. Flomoxef exhibit activity against epidermides, streptococci, propionibacteria, and both methicillin-resistant and -susceptible Staphylococcus aureus. Flomoxef appear to be stable to the common plasmid beta-lactamases TEM and SH4V-1 or by the betalactamases of S. aureus or B. fragilis.
semisynthetic oxacephem antibiotic that is stable to the common plasmid beta-lactamases TEM and SH4V-1
Storage Class
11 - Combustible Solids
wgk
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chen-Hsiang Lee et al.
Infection and drug resistance, 11, 2471-2480 (2018-12-21)
Flomoxef is potentially effective against β-lactamase-producing Enterobacteriaceae because limited clinical data demonstrate its effectiveness against Enterobacteriaceae bloodstream infections (BSIs) based on its minimum inhibitory concentrations (MICs). This study was conducted to determine the optimal breakpoints based on the survival of
H C Neu et al.
Antimicrobial agents and chemotherapy, 30(5), 638-644 (1986-11-01)
6315-S, a novel difluoromethyl thioacetamido oxacephem, had in vitro activity comparable to that of cefotaxime and moxalactam against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, Citrobacter diversus, Salmonella spp., and Shigella spp., inhibiting 90% at less than or equal
Jen-Jia Yang et al.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 51(5), 681-687 (2017-07-12)
Suppression of intestinal flora by broad-spectrum antimicrobial agents facilitated risk of colonization or infection with resistant pathogen. We aimed to investigate the changes in bowel carriage of target resistant microorganisms (TRO) among patients treated with three different classes of Pseudomonas-sparing
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service